Pyridoxine/P5P-dependent developmental epileptic encephalopathy …

Roberto H Caraballo MD

Epilepsy & Seizures

Updated 10.14.2024
Released 03.01.2000
Expires For CME 10.14.2027

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Author: Roberto H Caraballo MD

See Contributor Disclosures

Editor: Solomon L Moshé MD

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

In This Article

Quick Link

Introduction

This article includes discussion of pyridoxine-dependent epilepsy, vitamin B6-dependent seizures, pyridoxine-dependent seizures, classic neonatal pyridoxine-dependent seizures, and postneonatal pyridoxine-dependent epilepsy. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Overview

A newborn with refractory seizures controlled with pyridoxine was first reported in 1954, and for many years, no markers to identify this condition besides the therapeutic response were known. In more recent years, mutations in the ALDH7A1 gene encoding alpha-amino-adipic semialdehyde dehydrogenase (antiquitin) have been identified. In addition to the wide range of differential diagnoses with epileptic and nonepileptic seizures in infants, two other treatment-resistant epileptic conditions should be considered that occur in the neonatal and infancy period: pyridoxal phosphate deficiency and folinic acid responsive seizures.

Key points

• Pyridoxine dependency should be considered if:
	-- Family history shows:
		-- miscarriage -- stillbirth -- consanguineous parents -- a sibling with severe seizures or one who died of status epilepticus
	-- The infant shows:
		- unusual fetal movements suggestive of intrauterine seizures - seizures of unknown etiology in a previously normal infant - irritability, restlessness, hyperexcitability, and vomiting preceding clinical seizures - prolonged or recurrent seizures resistant to antiseizure medications
• In developing countries, performing genetic studies is difficult; thus, administration of pyridoxine in infants with drug-resistant seizures of unknown etiology is still very useful, not only from a therapeutic but also from a diagnostic point of view. Once a clinical diagnosis of pyridoxine dependency has been established by demonstrating cessation of seizures after the addition of pyridoxine to the treatment, biochemical and molecular studies are recommended.
• In an infant with good response to pyridoxine, the vitamins should be withdrawn to confirm the diagnosis. If the seizures recur, lifelong pyridoxine therapy is required.
• All infants under 2 years of age with drug-resistant seizures of unknown etiology should be given pyridoxine.
• Treatment of pyridoxine-dependent epilepsy is considered to be beneficial, even though prognosis may vary even after early treatment.

Historical note and terminology

Hunt and colleagues first described a girl who began twitching at 3 hours of life; she began experiencing generalized seizures at 5 days of age (47). The seizures were refractory to conventional antiseizure medications. An intramuscular injection of multivitamins controlled the seizures for 48 to 56 hours, whereas subsequent standard doses of oral vitamin supplements did not. Pyridoxine (vitamin B6) was eventually identified as the fraction of the multivitamin preparation responsible for clinical efficacy. Withdrawal of the vitamins led to seizure recurrence within 50 hours. The entity was named “pyridoxine dependency” to distinguish it from pyridoxine deficiency as the patient had no antecedents to suspect pyridoxine deficiency, and high doses of pyridoxine were necessary to control the seizures. A related condition designated as pyridoxine-responsive seizure includes infants and young children with seizures who respond initially to pyridoxine, but who lack seizure recurrence with pyridoxine withdrawal (07; 08). Pyridoxine-dependent epilepsy is considered as a prototypical form of metabolic epilepsy (92).

Clinical manifestations

Presentation and course

Classic neonatal form. Infants with pyridoxine dependency may initially present with episodes of restlessness, irritability, and occasionally hypotonia or poor feeding. Abnormal Apgar scores and cord blood gases may also be observed. For this reason, it is not uncommon for these newborns to be diagnosed with hypoxic-ischemic encephalopathy (08). Episodes of encephalopathy may be seen in older infants prior to recurrence of seizures and during intercurrent infection. The seizures typically begin soon after birth and can be of multiple types, such as focal or bilateral motor seizures, epileptic spasms, and myoclonic seizures. The seizures are refractory to standard antiseizure medications but respond well to pyridoxine administration; occasionally, untreated patients have died of status epilepticus. Developmental disabilities are commonly found, which may be independent of the timing of pyridoxine therapy (80). Prolonged seizures as status epilepticus have been associated with pyridoxine dependency in infants (98). Some patients present with intrauterine convulsions (11). There may also be a family history of a sibling who died of status epilepticus in infancy.

Infantile epileptic spasms syndrome with or without hypsarrhythmia is rare but may occur (38; 52). Kalser and colleagues reported a case of infantile spasms without hypsarrhythmia and paroxysmal eye-head movement associated with pyridoxine-dependent epilepsy due to pyridoxal 5'-phosphate-binding protein (PLPBP) / pyridoxal phosphate homeostasis protein (PLPHP) deficiency (52). On the other hand, our group studied a patient with infantile epileptic spasm syndrome who responded well to pyridoxine. Pyridoxine withdrawal led to recurrence of the seizures, which stopped again after restarting the vitamin. Unfortunately, genetic studies could not be performed.

Early-onset encephalopathy with burst suppression may also occur (50).

Late-onset seizures. Numerous “atypical” presentations of pyridoxine-dependent seizures have been described, mostly involving seizure onset beyond the neonatal period. Cases with seizure onset up to 30 months of age have been observed (43; 22). These late-onset cases are sometimes referred to as “postneonatal pyridoxine-dependent epilepsy.” The seizure types in late-presenting cases are less predictable than in early-onset ones. Generalized tonic or clonic seizures are frequently described. Focal seizures with or without secondary generalization have been reported as well (07; 20; 92). The late-onset form is more frequent than the classic neonatal form.

Prognosis and complications

Diagnosing pyridoxine-dependent epilepsy is important because early treatment improves outcome. Unfortunately, infants with early-onset seizures initially responsive to routine antiseizure medications have a poor prognosis. A correlation with the delay before treatment has been found. In early-onset pyridoxine-dependent epilepsy, a delay of up to 4 days does not seem to cause additional harm, whereas delays of more than 1 week are associated with an increased risk of learning difficulties and cerebral palsy. Patients with a later onset tolerate much longer delays without apparent harm (07).

Some evidence suggests that antenatal pyridoxine supplementation may be effective in preventing intrauterine seizures, decreasing the risk of complicated birth and improving neurodevelopmental outcome (13).

Additionally, the maintenance dose may have some influence on outcome (07). Nevertheless, even with early treatment, the outcome is poor, and many children show learning difficulties. Neuropsychological assessment shows that children who have been treated early are within the normal range but below average on nonverbal measures. On verbal tasks, their receptive verbal skills also show to be normal, but expressive language functions are impaired. This finding is typical in children with early-onset pyridoxine-dependent seizures but is less evident in children with later-onset forms. Children with the early-onset form may have severe articulatory dyspraxia and may need special schooling (07).

Clinical vignette

The patient, a 12-month-old girl, was born full-term; she became irritable and began having repetitive, brief, bilateral clonic seizures in the upper limbs at 1.5 months of age. The interictal EEGs as well as neuroradiological imaging and neurometabolic work-up were normal; all failed to identify an etiology. At 2 months of age, a pyridoxine trial was performed with 200 mg per day administered orally. At 5 months of age, withdrawal was attempted; pyridoxine was stopped abruptly, and the seizures recurred 7 days later. Pyridoxine was reintroduced, and the baby remained seizure-free for 7 months.

Her sister with mental retardation and refractory seizures that had started at 2 months of age died during status epilepticus when she was 4 years old; she never received pyridoxine. Her 16-year-old brother had drug-resistant seizures that started at 3 days of life; he developed severe encephalopathy. At 15 years of age, 400 mg/day of pyridoxine was introduced, and he improved significantly, both in regards to seizure frequency and alertness.

In this familial case, pyridoxine could be administered early because of the familial antecedents. However, in an infant under 2 years of age with refractory seizures without known etiology, the treatment with pyridoxine is always indicated.

Biological basis

Etiology and pathogenesis

Alpha-aminoadipic semialdehyde dehydrogenase (antiquitin) deficiency has been identified as a major cause of this disorder, leading to accumulation of both alpha-aminoadipic semialdehyde dehydrogenase and pipecolic acid in body fluids (17; 87). Elevated urinary concentration of alpha-aminoadipic semialdehyde is a more sensitive biomarker than pipecolic acid for pyridoxine-dependent epilepsy. Elevated plasma concentrations of alpha-aminoadipic semialdehyde are also present (82). Children with pyridoxine-dependent seizures have mutations in the ALDH7A1 gene encoding alpha-AASA dehydrogenase (62; 77; 12; 23). More than 165 pathogenic variants have been reported in the literature (23).

Pyridoxal-5-phosphate is involved as a cofactor in numerous enzymatic reactions including glutamic acid decarboxylase (GAD), which converts the excitatory neurotransmitter, glutamate, to gamma-amino-butyric acid (GABA), the principal inhibitory neurotransmitter in the mammalian CNS known to play important roles in the mechanisms of epileptic phenomena (21). Impaired electron transport chain function, accumulation of glutamate in the CNS, tricarboxylic acid cycle dysfunction in human ALDH7A1 pyridoxine-dependent epilepsy, an abnormal GABA pathway, tricarboxylic acid cycle, and electron transport chain in aldh7a1 knock-out zebrafish were found. It was suggested that CNS glutamate toxicity and impaired energy production may play important roles in the disease neuropathogenesis and severity in human pyridoxine-dependent epilepsy (64).

Abnormal activity of delta-1-piperideine-6-carboxylate (P6C)-α-AASA results in increased levels of P6C, which is the cyclic Schiff base of α-AASA. These two substances are in equilibrium with one another. P6C, in turn, inactivates pyridoxal-phosphate (PLP) by condensing with the cofactor, and this likely results in abnormal metabolism of the neurotransmitter (62).

AASA is formed by the catabolization of lysine through the saccharopine and pipecolate pathways and is then oxidized to aminoadipate (AAA) by antiquitin (ALDH7A1). In a mouse model, the saccharopine pathway was indicated to be primarily responsible for body’s production of AASA/P6C. This finding may lead to the development of new therapies for pyridoxine-dependent epilepsy targeted at inhibiting the saccharopine pathway upstream of AASA/P6C synthesis (74; 27). A study that evaluated the phenotype, biochemical features, genotype, and treatment outcome of pyridoxine-dependent epilepsy found no correlation between severity of the phenotype and the degree of α-AASA elevation in urine or genotype (02).

Mutations in a recombinant human antiquitin cDNA were generated and expressed in Escherichia coli. In the E coli expression system, all the mutants were stably expressed but lacked enzymatic activity. This finding is consistent with the pathogenicity of these mutations in vivo (26).

The presence of Roth spots in a patient with pyridoxine-dependent epilepsy may suggest a pathogenic mechanism of vasogenic damage (16).

Antiquitin is expressed within glial cells in the brain, and its dysfunction in pyridoxine-dependent epilepsy is associated with neuronal migration abnormalities and other structural brain defects. These malformations persist despite postnatal pyridoxine supplementation and likely contribute to neurodevelopmental impairments (48).

In a model of Aldh7a1-knock-out mice, Al-Shekaili and colleagues found evidence of an impaired amino acid profile and increased levels of methionine sulfoxide, an oxidative stress biomarker, in the mouse brains (01). This suggests that increased oxidative stress may be a novel pathobiochemical mechanism in ALDH7A1 deficiency. Previously, it was found that ALDH7A1 protects cells against oxidative stress through different pathways (19). These findings may lead to research into new treatment options using antioxidants as supplements or adjuvant therapy (97).

Knock-out ALDH7A1 zebrafish (75; 100) and mouse models (01) for pyridoxine-dependent epilepsy due to antiquitin deficiency may provide valuable insights into pyridoxine-dependent epilepsy pathophysiology. Further research may offer new opportunities for drug screening and improve neurodevelopmental outcomes for the condition.

Genetic studies and counseling. If ALDH7A1 pathogenic variants have been identified in an affected family member, carrier testing is possible in at-risk relatives for early diagnosis and treatment. Prenatal testing for pregnancies at increased risk may be possible at clinical laboratories that offer either testing of this particular gene or custom prenatal testing. In the case of parenthood planning, couples at risk may opt for preimplantation genetic diagnosis (PGD). Genetic counseling on risks and possibilities should be included in the management of these families (41).

A study in 185 subjects with a diagnosis of pyridoxine-dependent epilepsy has added 47 novel variants to the literature, resulting in a total of 165 reported pathogenic variants (23).

Differential diagnosis

Confusing conditions

Epileptic syndromes should be considered in the differential diagnosis, particularly familial types such as benign familial neonatal seizures and benign familial infantile seizures.

In symptomatic focal epilepsies, etiologic considerations include structural abnormalities (congenital malformations), infections (meningitis, encephalitis), neoplasms, hemorrhage, and cardiovascular causes (arteriovenous malformations, embolic stroke). Seizures secondary to common metabolic disturbances should also be considered. Epileptic syndromes as differential diagnoses of pyridoxine dependency are listed in Table 1.

Table 1. Epileptic Syndromes as Differential Diagnoses of Pyridoxine Dependency

• Self-limited familial and nonfamilial neonatal epilepsy
• Self-limited familial neonatal-infantile epilepsy
• Self-limited familial and nonfamilial infantile epilepsy
• West syndrome
• Epileptic spasms in clusters without hypsarrhythmia
• Structural focal epilepsies
• Unknown focal epilepsies

The list of differential diagnoses of pyridoxine-dependency and paroxysmal nonepileptic events in infancy is long. Table 2 lists the nonepileptic episodic events in infancy.

Table 2. Nonepileptic Events in Infancy as Differential Diagnoses of Pyridoxine Dependency

• Benign neonatal sleep myoclonus
• Hyperekplexia
• Increased Moro reflex and attacks of opisthotonos
• Tonic reflex episodes in infancy
• Sandifer syndrome
• Fejerman syndrome (benign myoclonus of early infancy, including shuddering attacks)
• Benign paroxysmal tonic upward gaze
• Adverse reactions or intolerance to exogenous agents
• Paroxysmal dystonia and choreoathetosis
• Self-gratification or masturbation-like episodes

Associated or underlying disorders

Pyridoxine dependency should be suspected if:

	• Family history shows:
		- miscarriage - still birth - consanguineous parents - a sibling with severe convulsions or one who died of status epilepticus
	• The infant shows:
		- unusual fetal movements suggestive of intrauterine convulsions - seizures of unknown etiology in a previously normal infant - irritability, restlessness, hyperexcitability, and vomiting preceding clinical seizures - prolonged or recurrent seizures resistant to standard antiseizure medications

In neonates and infants without demonstrable brain lesions, metabolic causes (eg, hypocalcemia, hypoglycemia, hyponatremia) and inborn errors of metabolism (eg, urea cycle disorders, nonketotic hyperglycinemia, organic acidurias, biotin disorders, and pyruvate dehydrogenase deficiency) should be ruled out, as well as molybdenum cofactor deficiency and isolated sulfite oxidase deficiency, in which levels of α-AASA are also high (60).

Two pyridoxine-dependent epilepsies should be considered in the differential diagnosis in certain pyridoxine-dependent epilepsy patients with no mutation of the ALDH7A1 gene:

PNPO-associated pyridoxine-dependent epilepsy is caused by biallelic pathogenic variants in the pyridoxine-5′-phosphateoxidase (PNPO) gene. In these patients, pyridoxine is ineffective, whereas administration of pyridoxal phosphate results in a clinical response (63; 40; 46; 71). A study challenges the paradigm of exclusive PLP responsiveness in patients with pyridoxal 5′-phosphate oxidase deficiency and underlines the importance of consecutive testing of pyridoxine and PLP in neonates with antiseizure medication-resistant seizures. Patients with pyridoxine response but normal biomarkers for antiquitin deficiency should undergo PNPO mutation analysis (73).

Partial responsiveness to pyridoxine in patients with PNPO deficiency and a mutation in the 3:c.352G > A p.Gly118R gene is known (66). A child with this mutation, riboflavin dependence, and transient worsening of seizures off pyridoxine has been described. This case highlights the importance of identifying the precise gene mutation sequence to properly identify variants relative to individual phenotypic expression, treatment responsiveness, and need for added vitamin supplementation (66).

PLPBP-associated pyridoxine-dependent epilepsy or PLP binding protein deficiency is caused by biallelic pathogenic variants in the PLPBP gene (previously named PROSC) encoding a pyridoxal-phosphate-binding protein (28; 49; 51). The early-onset intractable seizures in PLPHP deficiency are responsive to pyridoxine and/or PLP. Patients show developmental delay and structural brain abnormalities, most notably a simplified gyral pattern and cyst-like structures adjacent to the anterior horns (28; 78; 51). PLPBP-associated pyridoxine-dependent epilepsy is rare and only a few patients are reported (51).

A founder mutation in the PLPBP gene was identified in a French Canadian region by whole exome sequencing of three unrelated families showing a homozygous pathogenic mutation c.370_373del, p.Asp124fs in five persons (72).

Finally, the diagnosis of pyridoxine deficiency should be considered as well. The deficiency can be due to insufficient dietary intake, gastrointestinal malabsorptive states, liver diseases, and leukemia. Relative depletion states due to increased metabolic demands are also possible (eg, hyperthyroidism). Isoniazid therapy causes a decrease in vitamin B6 levels. The clinical manifestations are similar in both the pyridoxine-deficiency and pyridoxine-dependency state, but peripheral neuritis, dermatitis, and anemia are only associated with the deficiency state. Increased concentration of α-aminoadipic semialdehyde (α-AASA) in urine and/or plasma identifies the pyridoxine-dependent state.

Diagnostic workup

The rare occurrence of this disease, its heterogeneous presentation, and variable response to treatment make the diagnosis difficult. However, measurement of urinary alpha-AASA is a simple way of confirming the diagnosis of pyridoxine-dependent seizures, and ALDH7A1 gene analysis provides a means for prenatal diagnosis.

Beyond the laboratory tests, neuroimaging, and other supportive studies warranted by the history and physical exam, a pyridoxine challenge may be part of the diagnostic work-up for a pediatric patient with medically refractory seizures of unknown etiology.

In practice, pyridoxine challenges are usually associated with antiseizure medications. The Neonatal Task Force of the International League Against Epilepsy (ILAE) recommends considering a pyridoxine trial as an adjunct to antiseizure medications for neonates who exhibit clinical or EEG features suggestive of vitamin B6–dependent epilepsy, as well as for those with seizures unresponsive to second-line antiseizure medications when no underlying cause is identified (79). In such a trial, cessation of seizure activity in response to pyridoxine would be suggestive, but not conclusive, of pyridoxine dependency. To confirm the diagnosis, pyridoxine therapy would have to be discontinued, followed by seizures that again respond to pyridoxine. Pipecolic acid in plasma and cerebral spinal fluid may serve as a nonspecific diagnostic marker for this disorder (76). Pyridoxine challenge is especially valid in countries where measurement of urinary alpha-AASA and ALDH7A1 gene analysis is not possible (20; 92). In pyridoxine-dependent epilepsy, simultaneous quantification of multiple lysine metabolites, including α-aminoadipic semialdehyde, piperideine-6-carboxylate, pipecolic acid, and α-aminoadipic acid in plasma, serum, dried blood spots, urine, and dried urine spots might play an important role not only in the diagnosis but also in the management of the disorder (96).

Intravenous pyridoxine should be given with concurrent clinical and EEG monitoring. The classic response is a dramatic cessation of ongoing seizures, usually within 10 minutes of injection. The EEG usually normalizes a few minutes later. In some cases, seizures take up to 1 hour to stop, and the EEG may take several hours to normalize (85).

Sometimes, however, the response to pharmacological doses of pyridoxine or PLP may not be immediate and total (95; 36). An adequate trial of pyridoxine (minimum 72 hours) with careful clinical and EEG monitoring is necessary, and if there is any sign of improvement, pyridoxine should be continued. A repeat trial should be considered if seizures remain poorly controlled.

There is a tendency to regard structural brain abnormalities as a sufficient cause of epilepsy; therefore, alternative diagnoses, such as pyridoxine deficiency, may be missed (61). The diagnosis of pyridoxine deficiency may also be difficult due to the possibility of multisystem pathology in neonates and infants. Thus, Mills and colleagues consider it useful to perform a biochemical and DNA test for antiquitin deficiency in a wide range of infants with epilepsy (61).

Different groups have identified novel biomarkers for pyridoxine-dependent epilepsy that may be used in current newborn screening programs in a cost-effective manner (57; 94). 2S,6S-/2S,6R-oxopropylpiperidine-2-carboxylic acid (2-OPP) was identified and suggested as a potential newborn screening biomarker for pyridoxine-dependent seizures in dried bloodspots (33).

Management

Patients need lifelong supplements of pyridoxine. Currently, there are no controlled studies to define the optimal dose due to the rarity of the disorder (41). The International PDE Consortium has published clinical practice guidelines for pyridoxine-dependent epilepsy (24). The doses of pyridoxine recommended by age are in newborns 100 mg/day, in infants 30 mg/kg/day with a maximum of 300 mg/day, and in children, adolescents, and adults 30 mg/kg/day with a maximum of 500 mg/day. In times of seizure exacerbation during an acute illness, the dose of pyridoxine may be doubled up to a maximum of 60 mg/kg/day (in children) or 500 mg/day (adolescents and adults) for up to 3 days. In addition, in times of illness adequate caloric intake should be ensured to prevent catabolism of endogenous protein and protein intake should be reduced (24; 33).

High doses carry the risk of developing a reversible peripheral sensory neuropathy. The risk of peripheral neuropathy must be weighed against the potential neurodevelopmental benefits of increased doses of pyridoxine. Adjustment of the dose of pyridoxine might prevent the development of intellectual disability and produce remission of seizures and normalization of CSF glutamate (06). In a patient with pyridoxine-dependent seizures with a partial response to vitamin B6, folinic acid should be added (83). Urinary alpha-aminoadipic semialdehyde is a reliable biomarker of pyridoxine-dependent epilepsy, even under pyridoxine treatment with good evolution; thus, antiquitin gene analysis should be performed (70).

In patients with folinic acid–responsive seizures associated with alpha-AASA dehydrogenase deficiency and mutations in the ALDH7A1 gene, the recommended dose of folinic acid is 2.5 to 5 mg twice daily. If seizures recur, an increase in folinic acid up to 8 mg/kg/day can be used, together with antiseizure medications, if necessary (88). Treatment with both pyridoxine and folinic acid as well as a lysine-restricted diet to reduce alpha-AASA levels may be considered (37). The International PDE Consortium has published additional guidelines for the dietary management for pyridoxine-dependent epilepsy due to alpha-AASA dehydrogenase deficiency (30).

Dietary lysine restriction as an adjunct to pyridoxine therapy was well tolerated with significant decrease of potentially neurotoxic biomarkers and with the potential to improve developmental outcomes and seizure control in children with pyridoxine-dependent epilepsy caused by antiquin deficiency (85; 91; 99; 53). Arginine fortification has proven safe as an add-on treatment to lysine restriction as well as effective in improving outcomes. Arginine supplement of 400 mg/kg/day, together with pyridoxine 200 mg/kg/day, a decrease in CSF alpha-AASA, and improvement in general abilities as well as verbal and motor functions were reported (58; 92; 55). Triple therapy (pyridoxine, lysine-restricted diet, and arginine supplementation) is tried with the aim to improve epilepsy control and neurocognitive development in patients with pyridoxine-dependent epilepsy (55; 65).

It should be taken into account that despite seizure control, neurodevelopment is normal in only 25% of the pyridoxine-treated patients (05; 15; 35). On the other hand, lysine-reduction therapies have resulted in improved biochemical parameters and cognitive development in many but not all patients (18; 24; 86). However, if the treatment with pyridoxine and lysine-reduction therapies was started in the first 6 months of life, it was associated with a significant improvement on developmental testing (25). Two systematic reviews found a statistically significant correlation between the early use of pyridoxine and improved long-term neurologic outcomes (34; 35).

Mutations in ALDH7A1, MOCS2, and ALDH4A1 are found to lead to build-up of reactive aldehydes (α-aminoadipic semialdehyde, γ-glutamic semialdehyde) that may react nonenzymatically with macromolecules of brain cells. Such reactions may produce "advanced glycation end products" (AGEs). AGEs trigger inflammation in the brain. Development of aldehyde-quenching, anti-AGE, or anti-inflammatory therapies may, therefore, be possible strategies to protect cognitive development and prevent intellectual disability in children with pyridoxine-dependent epilepsy (44).

Outcomes

Vitamin therapy may cause considerable adverse effects. Some studies report patients presenting with neurologic manifestations and respiratory distress as a result of a pyridoxine challenge. Severity of the side effects of pyridoxine therapy ranges from excessive sleepiness and lethargy to hypotonia, hypotension, hypothermia, bradycardia, and prolonged apnea requiring intubation and assisted ventilation (45; 54; 59; 89; 04; 67).

Prognosis for seizure control is excellent in compliant pyridoxine-dependent patients. However, most children with this disorder have some degree of intellectual disability, regardless of the age of diagnosis and treatment (05; 61). Neurodevelopment is normal in only 25% of pyridoxine-treated patients (05; 15). Early diagnosis and treatment are encouraged.

A small subgroup of patients with pyridoxine-dependent epilepsy is characterized by late-onset beyond 2 months of age. In this subgroup, a relatively good cognitive outcome was observed. De Rooy and colleagues studied four late-onset patients who had a relatively good cognitive outcome (29). No clear association was found between ALDH7A1 mutations, α-AASA and pipecolic acid levels, medication during pregnancy, delivery, treatment delay, number of seizures, pyridoxine dose, adjuvant therapy, and findings on brain MRI. Nevertheless, it was speculated that a less severe genotype may be present in three patients, and maternal medication could be accountable for better outcome in two patients. Therefore, the better outcome may be related to a combination of factors: a yet unknown protective factor, different genetic variations, functional variation and secondarily variation in treatment regimens, and absence of neonatal-seizure-induced brain damage (29).

References

01: Al-Shekaili HH, Petkau TL, Pena I, et al. A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency. Hum Mol Genet 2020;29(19):3266-84. PMID 32969477
02: Al Teneiji A, Bruun TU, Cordeiro D, et al. Phenotype, biochemical features, genotype and treatment outcome of pyridoxine-dependent epilepsy. Metab Brain Dis 2017;32(2):443-51. PMID 27882480
03: Arntsen V, Jamali A, Sikiric A, et al. Utility and limitations of EEG in the diagnosis and management of ALDH7A1-related pyridoxine-dependent epilepsy. A retrospective observational study. Front Neurol 2024;15:1355861. PMID 38419708
04: Bass NE, Wyllie E, Cohen B, Joseph SA. Pyridoxine-dependent epilepsy: the need for repeated pyridoxine trials and the risk of severe electrocerebral suppression with intravenous pyridoxine infusion. J Child Neurol 1996;11:422-4. PMID 8877616
05: Basura GJ, Hagland SP, Wiltse AM, Gospe SM Jr. Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures review of 63 North American cases submitted to a patient registry. Eur J Pediatr 2009;168:697-704.** PMID 18762976
06: Baumeister FA, Gsell W, Shin YS, Egger J. Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. Pediatrics 1994;94:318-21. PMID 7915028
07: Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. Dev Med Child Neurol 2001a;43:416-20.** PMID 11409832
08: Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. In: Baxter P, editor. Vitamin-Responsive Conditions in Paediatric Neurology. Mac Keith Press, 2001b:109-65.
09: Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 1996;38:998-1006. PMID 8913181
10: Been JV, Bok LA, Andriessen P, Renier WO. Epidemiology of pyridoxine dependent seizures in the Netherlands. Arch Dis Child 2005;90(12):1293-6. PMID 16159904
11: Bejsovec M, Kulenda Z, Ponca E. Familial intrauterine convulsions in pyridoxine dependency. Arch Dis Child 1967;42:201-7. PMID 6024470
12: Bennett CL, Chen Y, Hahn S, Glass IA, Gospe SM Jr. Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients. Epilepsia 2009;50(5):1167-75. PMID 19128417
13: Bok L, Been JV, Struys EA, Jakobs C, Rijper EA, Willemsen M. Antenatal treatment in two Dutch families with pyridoxine-dependent epilepsy. Eur J Pediat 2010a;169:297-303. PMID 19588165
14: Bok L, Maurits N, Willemsen M, et al. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. Epilepsia 2010b;51(12):2406-11. PMID 20887371
15: Bok LA, Halbertsma FJ, Houterman S, et al. Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol 2012;54(9):849-54.** PMID 22804844
16: Bok LA, Halbertsma F, Kerkhoff F, Jakobs C, Duijsters C, Willemsen M. Roth spots in pyridoxine dependent epilepsy. BMJ Case Rep 2011;2011. PMID 22688935
17: Bok LA, Struys E, Willemsen MA, Been JV, Jakobs C. Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Arch Dis Child 2007;92(8):687-9. PMID 17088338
18: Bouchereau J, Schiff M. Inherited disorders of lysine metabolism: a review. J Nutr 2020;150(Suppl 1):2556S-60S. PMID 33000154
19: Brocker C, Cantore M, Failli P, Vasiliou V. Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. Chem Biol Interact 2011;191(1-3):269-77. PMID 21338592
20: Caraballo R, Garro F, Cersósimo R, Buompadre C, Ganez LA, Fejerman N. Dependencia de Piridoxina: valor del diagnóstico clínico y del tratamiento precoz. Rev Neurol (Barc) 2004;38(1):49-52. PMID 14730491
21: Chang FM. Update current understanding of neurometabolic disorders related to lysine metabolism. Epilepsy Behav 2023;146:109363. PMID 37499576
22: Coker S. Postneonatal vitamin B6-dependent epilepsy. Pediatrics 1992;90:221-3. PMID 1641285
23: Coughlin CR II, Swanson MA, Spector E, et al. The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: a common epileptic encephalopathy. J Inherit Metab Dis 2019;42(2):353-61.** PMID 30043187
24: Coughlin CR 2nd, Tseng LA, Abdenur JE, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 2021;44(1):178-92.** PMID 33200442
25: Coughlin CR 2nd, Tseng LA, Bok LA, et al. Association between lysine reduction therapies and cognitive outcomes in patients with pyridoxine-dependent epilepsy. Neurology 2022;99(23):e2627-36. PMID 36008148
26: Coulter-Mackie M, Li A, Lian Q, Struys E, Stockler S, Waters PJ. Overexpression of human antiquitin in E. coli enzymatic characterization of twelve ALDH7A1 missense mutations associated with pyridoxine-dependent epilepsy. Mol Genet Metab 2012;54(9):478-81. PMID 22784480
27: Crowther LM, Mathis D, Poms M, Plecko B. New insights into human lysine degradation pathways with relevance to pyridoxine-dependent epilepsy due to antiquitin deficiency. J Inherit Metab Dis 2019;42(4):620-8.** PMID 30767241
28: Darin N, Reid E, Prunetti L, et al. Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B6-dependent epilepsy. Am J Hum Genet 2016;99(6):1325-37. PMID 27912044
29: de Rooy RLP, Halbertsma FJ, Struijs EA, et al. Pyridoxine dependent epilepsy: is late onset a predictor for favorable outcome? Eur J Paediatr Neurol 2018;22(4):662-6. PMID 29661537
30: Dixon M, Millington C, Bernstein L, et al. Dietary management for pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency, a follow-on from the international consortium guidelines. JIMD Rep 2024;65(3):188-203. PMID 38736635
31: Dogan M, Dogan DG, Kahraman AS, Ozcan O, Yakinci C, Alkan A. A 9-year follow-up of a girl with pyridoxine (vitamin B6)-dependent seizures: magnetic resonance spectroscopy findings. Eur Rev Med Pharmacol Sci 2012;16(5):695-8. PMID 22774414
32: Ebinger M, Schultze C, Konig S. Demographics and diagnosis of pyridoxine dependent seizures (letter). J Pediatr 1999;134(6):795-6. PMID 10356240
33: Engelke UF, van Outersterp RE, Merx J, et al. Untargeted metabolomics and infrared ion spectroscopy identify biomarkers for pyridoxine-dependent epilepsy. J Clin Invest 2021;131(15):e148272. PMID 34138754
34: Falsaperla R, Sciacca M, Collotta AD, et al. PYRIDOXINE-dependent epilepsy (PDE): an observational study of neonatal cases on the role of pyridoxine in patients treated with standard anti-seizure medications. Seizure 2024;118:156-63. PMID 38735085
35: Fang C, Yang L, Xiao F, Yan K, Zhou W. Genotype and phenotype features and prognostic factors of neonatal-onset pyridoxine-dependent epilepsy: a systematic review. Epilepsy Res 2024;202:107363. PMID 38636407
36: Fortin O, Christoffel K, Kousa Y, et al. Pearls & oy-sters: delayed response to pyridoxine in pyridoxine-dependent epilepsy. Neurology 2023;101(18):e1828-32. PMID 37580162
37: Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 2009;65(5):550-6. PMID 19142996
38: Gibaud M, Barth M, Lefranc J, et al. West syndrome is an exceptional presentation of pyridoxine- and pyridoxal phosphate-dependent epilepsy: data from a French cohort and review of the literature. Front Pediatr 2021;9:621200. PMID 33748042
39: Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 2002;26:181-5. PMID 11955923
40: Gospe SM. Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment. Curr Opin Neurol 2006;19(2):148-53. PMID 16538088
41: Gospe SM Jr. Pyridoxine-dependent epilepsy–ALDH7A1. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; December 7, 2001 [updated 2021 Jul 29]. PMID 20301659
42: Gospe SM Jr, Olin KL, Keen CL. Reduced GABA synthesis in pyridoxine-dependent seizures. Lancet 1994;343:1133-4. PMID 7910233
43: Goutieres F, Aicardi J. Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants. Ann Neurol 1985;17:117-20. PMID 3977296
44: Hassel B, Rogne AG, Hope S. Intellectual disability associated with pyridoxine-responsive epilepsies: the need to protect cognitive development. Front Psychiatry 2019;10:116. PMID 30930802
45: Heeley A, Pugh RJ, Clayton BE, Sheerd J, Wilson J. Pyridoxal metabolism in vitamin B6-responsive convulsions of early infancy. Arch Dis Child 1978;53:794-802. PMID 727793
46: Hoffmann GF, Schmitt B, Windfuhr M, et al. Pyridoxal 5’-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 2007;30:96-9. PMID 17216302
47: Hunt AD Jr, Stokes J Jr, McCrory WW, Stroud HH. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics 1954;13:140-5. PMID 13133562
48: Jansen LA, Hevner RF, Roden WH, Hahn SH, Jung S, Gospe SM Jr. Glial localization of antiquitin: implications for pyridoxine-dependent epilepsy. Ann Neurol 2014;75(1):22-32. PMID 24122892
49: Jensen KV, Frid M, Stödberg T, et al. Diagnostic pitfalls in vitamin B6-dependent epilepsy caused by mutations in the PLPBP gene. JIMD Rep 2019;50(1):1-8. PMID 31741821
50: Jiao X, Gong P, Niu Y, Zhang Y, Yang Z. A rare presentation characterized by epileptic spasms in ALDH7A1, pyridox(am)ine-5'-phosphate oxidase, and PLPBP deficiency. Front Genet 2022;13:804461. PMID 35495162
51: Johnstone DL, Al-Shekaili HH, Tarailo-Graovac M, et al. PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights. Brain 2019;142(3):542-59. PMID 30668673
52: Kalser J, Giuliano F, Peralta M, Plecko B, Bölsterli BK. Infantile spasms without hypsarrhythmia and paroxysmal eye-head movements in an infant with a pyridoxine-dependent epilepsy due to PLPBP/PLPHP deficiency. Neuropediatrics 2023;54(6):422-5. PMID 36577449
53: Kava MP, Bryant L, Rowe P, Lewis B, Greed L, Balasubramaniam S. Beneficial outcome of early dietary lysine restriction as an adjunct to pyridoxine therapy in a child with pyridoxine dependant epilepsy due to Antiquitin deficiency. JIMD Rep 2020;54(1):9-15. PMID 32685344
54: Kroll JS. Pyridoxine for neonatal seizures: an unexpected danger. Dev Med Child Neurol 1985;27:369-82. PMID 4018433
55: Mahajnah M, Corderio D, Austin V, et al. A prospective case study of the safety and efficacy of lysine-restricted diet and arginine supplementation therapy in a patient with pyridoxine-dependent epilepsy caused by mutations in ALDH7A1. Pediatr Neurol 2016;60:60-5. PMID 27212567
56: Marguet F, Barakizou H, Tebani A, et al. Pyridoxine-dependent epilepsy: report on three families with neuropathology. Metab Brain Dis 2016;31(6):1435-43. PMID 27438048
57: Mathew EM, Moorkoth S, Lewis L, Rao P. Biomarker profiling for pyridoxine dependent epilepsy in dried blood spots by HILIC-ESI-MS. Int J Anal Chem 2018;2018:2583215. PMID 30154848
58: Mercimek-Mahmutoglu S, Cordeiro D, Cruz V, et al. Novel therapy for pyridoxine dependent epilepsy due to ALDH7 A1 genetic defect: L-arginine supplementation alternative to lysine-restricted diet. Eur J Paediatr Neurol 2014;18(6):741-6. PMID 25127453
59: Mikati MA, Trevathan E, Krishnamoorthy KS, Lombroso CT. Pyridoxine-dependent epilepsy: EEG investigations and long-term follow-up. Electroencephalogr Clin Neurophysiol 1991;78(3):215-21. PMID 1707793
60: Mills PB, Footitt EJ, Ceyhan S, et al. Urinary AASA excretion is elevated in patients with molybdenum cofactor deficiency and isolated sulphite oxidase deficiency. J Inherit Metab Dis 2012;35(6):1031-6. PMID 22403017
61: Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010;133:2148-59.** PMID 20554659
62: Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006;12:307-9. PMID 16491085
63: Mills PB, Surtees RA, Champion MP, et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5’-phosphate oxidase. Hum Mol Genet 2005;14:1077-86. PMID 15772097
64: Minenkova A, Jansen EEW, Cameron J, et al. Is impaired energy production a novel insight into the pathogenesis of pyridoxine-dependent epilepsy due to biallelic variants in ALDH7A1? PLoS One 2021;16(9):e0257073. PMID 34495967
65: Minet P, Sarret C, Miret A, Mention K, Benoist JF, Remerand G. Clinical and biochemical outcome of a patient with pyridoxine-dependent epilepsy treated by triple therapy (pyridoxine supplementation, lysine-restricted diet, and arginine supplementation). Acta Neurol Belg 2021;121(6):1669-75. PMID 33113107
66: Mohanlal S, Bindu PS, Sureshbabu S, Kumar S. Variable treatment response in a patient with pyridoxal N phosphate oxidase (PNPO) deficiency- understanding the paradox. Epilepsy Behav Rep 2020;14:100357. PMID 32395712
67: Nabbout R, Soufflet C, Plouin P, Dulac O. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed 1999;81:F125-9. PMID 10448181
68: Naassan G, Yabroudi M, Rahi A, Mikati MA. Electroencephalographic changes in pyridoxine-dependent epilepsy: new observations. Epileptic Disord 2009;11:293-300. PMID 20031502
69: Navarro-Abia V, Soriano-Ramos M, Núñez-Enamorado N, et al. Hydrocephalus in pyridoxine-dependent epilepsy: New case and literature review. Brain Dev 2018;40(4):348-52. PMID 29295802
70: Oliveira R, Pereira C, Rodrigues F, et al. Pyridoxine-dependent epilepsy due to antiquitin deficiency: achieving a favourable outcome. Epileptic Disord 2013;15(4):400-6. PMID 24184718
71: Ormazabal A, Oppenheim M, Serrano M, et al. Pyridoxal 5’-phosphate values in cerebrospinal fluid: reference values and diagnosis of PNPO deficiency in paediatric patients. Mol Genet Metab 2008;94:173-7. PMID 18294893
72: Pal M, Lace B, Labrie Y, et al. A founder mutation in the PLPBP gene in families from Saguenay-Lac-St-Jean region affected by a pyridoxine-dependent epilepsy. JIMD Rep 2021;59(1):32-41. PMID 33977028
73: Pearl PL, Gospe SM Jr. Pyridoxine or pyridoxal-5'-phosphate for neonatal epilepsy: The distinction just got murkier. Neurology 2014;82(16):1392-4. PMID 24658927
74: Pena IA, Marques LA, Laranjeira ÂB, et al. Mouse lysine catabolism to aminoadipate occurs primarily through the saccharopine pathway; implications for pyridoxine dependent epilepsy (PDE). Biochim Biophys Acta 2017a;1863(1):121-8. PMID 27615426
75: Pena IA, Roussel Y, Daniel K, et al. Pyridoxine-dependent epilepsy in zebrafish caused by aldh7a1 deficiency. Genetics 2017b;207(4):1501-18. PMID 29061647
76: Plecko B, Hikel C, Korenke GC, et al. Pipecolic acid as a diagnostic marker of pyridoxine-dependent epilepsy. Neuropediatrics 2005;36:200-5. PMID 15944906
77: Plecko B, Paul K, Paschke E, et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007;28(1):19-26. PMID 17068770
78: Plecko B, Zweier M, Begemann A, et al. Confirmation of mutations in PROSC as a novel cause of vitamin B6 -dependent epilepsy. J Med Genet 2017;54(12):809-14. PMID 28391250
79: Pressler RM, Abend NS, Auvin S. Treatment of seizures in the neonate: guidelines and consensus-based recommendations-special report from the ILAE Task Force on Neonatal Seizures. Epilepsia 2023;64(10):2550-70. PMID 37655702
80: Rankin PM, Harrison S, Chong WK, Boyd S, Aylett SE. Pyridoxine-dependent seizures: a family phenotype that leads to severe cognitive deficits, regardless of treatment regime. Dev Med Child Neurol 2007;49(4):300-5. PMID 17376142
81: Russell KE, Mulligan SR, Mallory LA. Diagnosis of pyridoxine-dependent seizures in a nineteen-year-old patient. Pediatr Neurol 2012;47(2):141-3. PMID 22759694
82: Sadilkova K, Gospe SM Jr, Hahn SH. Simultaneous determination of alpha-aminoadipic semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for pyridoxine-dependent seizures and folinic acid-responsive seizures. J Neurosci Methods 2009;184(1):136-41. PMID 19631689
83: Segal EB, Grinspan ZM, Mandel AM, Gospe SM. Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy. Pediatr Neurol 2011;44(4):289-91. PMID 21397171
84: Srinivasaraghavan R, Parameswaran N, Mathis D, Bürer C, Plecko B. Antiquitin deficiency with adolescent onset epilepsy: molecular diagnosis in a mother of affected offsprings. Neuropediatrics 2018;49(2):154-7. PMID 29401530
85: Stockler S, Plecko B, Gospe SM, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011;104(1-2):48-60.** PMID 21704546
86: Strijker M, Tseng LA, van Avezaath LK, et al. Cognitive and neurological outcome of patients in the Dutch pyridoxine-dependent epilepsy (PDE-ALDH7A1) cohort, a cross-sectional study. Eur J Paediatr Neurol 2021;33:112-20. PMID 34153871
87: Struys EA, Jakobs C. Alpha-aminoadipic semialdehyde is the biomarker for pyridoxine dependent epilepsy caused by alpha-aminoadipic semialdehyde dehydrogenase deficiency. Mol Genet Metab 2007;91(4):384-9. PMID 17560822
88: Surtees R, Wolf N. Treatable neonatal epilepsy. Arch Dis Child 2007;92(8):659-61. PMID 17642476
89: Tanaka R, Okumura M, Arima J, Yamakura S, Momoi T. Pyridoxine-dependent seizures: report of a case with atypical clinical features and abnormal MRI scans. J Child Neurol 1992;7:24-8. PMID 1552147
90: Teune LK, vd Hoeven JH, Maurits NM, et al. Pyridoxine induces non-specific EEG alterations in infants with therapy resistant seizures. Seizure 2007;16(5):459-64. PMID 17408982
91: van Karnebeek CD, Hartmann H, Jaggumantri S, et al. Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials. Mol Genet Metab 2012;107(3):335-44. PMID 23022070
92: van Karnebeek CD, Jaggumantri S. Current treatment and management of pyridoxine-dependent epilepsy. Curr Treat Options Neurol 2015;17(2):335. PMID 25639976
93: van Karnebeek C, Tiebout S, Niermeijer J, et al. Pyridoxine-Dependent Epilepsy: An expanding clinical spectrum. Pediatr Neurol 2016;59:6-12.** PMID 26995068
94: Wempe MF, Kumar A, Kumar V, et al. Identification of a novel biomarker for pyridoxine-dependent epilepsy: implications for newborn screening. J Inherit Metab Dis 2019;42(3):565-74. PMID 30663059
95: Wilson MP, Plecko B, Mills PB, Clayton PT. Disorders affecting vitamin B6 metabolism. J Inherit Metab Dis 2019;42(4):629-46. PMID 30671974
96: Xue J, Wang J, Gong P, et al. Simultaneous quantification of alpha-aminoadipic semialdehyde, piperideine-6-carboxylate, pipecolic acid and alpha-aminoadipic acid in pyridoxine-dependent epilepsy. Sci Rep 2019;9(1):11371. PMID 31388081
97: Yazdani M, Elgstøen KBP. Is oxidative stress an overlooked player in pyridoxine-dependent epilepsy? A focused review. Seizure 2021;91:369-73. PMID 34298455
98: Yoshii A, Takeoka M, Kelly PJ, Krishnamoorthy KS. Focal status epilepticus as atypical presentation of pyridoxine-dependent epilepsy. J Child Neurol 2005;20(8):696-8. PMID 16225819
99: Yuzyuk T, Thomas A, Viau K, et al. Effect of dietary lysine restriction and arginine supplementation in two patients with pyridoxine-dependent epilepsy. Mol Genet Metab 2016;118(3):167-72. PMID 27324284
100: Zabinyakov N, Bullivant G, Cao F, et al. Characterization of the first knock-out aldh7a1 zebrafish model for pyridoxine-dependent epilepsy using CRISPR-Cas9 technology. PLoS One 2017;12(10):e0186645. PMID 29053735

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Roberto H Caraballo MD

Dr. Caraballo of Hospital Nacional de Pediatria Juan P Garrahan has no relevant financial relationships to disclose.
See Profile

Editor

Solomon L Moshé MD

Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

John Kuratani MD
Natalio Fejerman MD

Patient Profile

Age range of presentation: 0 to 30 months
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Associated Disorders

Cortical atrophy
Developmental delay
Intellectual disability
Pyridoxine-dependent seizure
Status epilepticus

Differential Diagnosis

hypocalcemia
hypoglycemia
hyponatremia
inborn errors of metabolism
urea cycle disorders
- nonketotic hyperglycinemia
- organic acidurias
- biotin disorders
- molybdenum cofactor deficiency
- pyruvate dehydrogenase deficiency
- pyridoxal phosphate (PLP) responsive seizures
- folinic acid responsive seizures
- congenital folate malabsorption
- syndromes of defective cellular utilization because of enzymatic deficiencies
- methylenetetrahydrofolate reductase deficiency
- 5-methylenetetrahydrofolate reductase deficiency
- pyridoxine deficiency
- self-limited familial and nonfamilial neonatal epilepsy
- self-limited familial neonatal-infantile epilepsy
- self-limited familial and nonfamilial infantile epilepsy
- West syndrome
- epileptic spasms in cluster without hypsarrhythmia
- structural focal epilepsies
- epilepsy of unknown etiology
- benign neonatal sleep myoclonus
- hyperekplexia
- increased Moro reflex and attacks of opisthotonos
- tonic reflex episodes in infancy
- Sandifer syndrome
- Fejerman syndrome (benign myoclonus of early infancy, including shuddering attacks)
- benign paroxysmal tonic upward gaze
- adverse reactions or intolerance to exogenous agents
- paroxysmal dystonia and choreoathetosis
- self-gratification or masturbation-like episodes

Also Relevant

Epilepsy
Neonatal seizures
Pyridoxine deficiency and toxicity
West syndrome
White matter abnormalities in the brain

Clinical Categories

Patient Handouts

Web References

Guidelines

Clinical Trials

NIH: Epilepsy

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Other atypical presentations

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Table 1. Epileptic Syndromes as Differential Diagnoses of Pyridoxine Dependency

Table 2. Nonepileptic Events in Infancy as Differential Diagnoses of Pyridoxine Dependency

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Photosensitive occipital lobe epilepsy

Breath-holding spells

Intermittent explosive disorder

Neonatal status epilepticus

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

This is an article preview.
Start a Free Account
to access the full version.